To examine whether palmitoylation affects the development of pancreatic cancer, we used the KPC (LSL- KRAS G12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) mouse model23 to examine the effect of 2-bromopalmitate (2-BP) on pancreatic cancer progression (Fig. 1A). Here, KRAS is linked to pancreatic neoplasm.